Possible association between lipid profile and uterine fibroid size
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20231905Keywords:
Association, Lipid profile, Size, Uterine fibroidAbstract
Background: Uterine fibroid is the most common benign tumor in reproductive age group, arising from single smooth muscle cell of the uterus. Steroid hormones, estrogen, and progesterone are considered to be the most important links in the pathophysiology of uterine fibroid; meanwhile estrogens influence several aspects of lipid metabolism; so it's possible to theorize a relationship between uterine fibroid size and dyslipidemia. Aim of the study was to evaluate possible association of lipid profile with uterine fibroid size.
Methods: This was a cross sectional study performed in Babylon Teaching Hospital for Maternity and Pediatrics during the period from 1st of March 2020- 1st of December 2020. This study included one hundred women diagnosed with uterine fibroid using abdominal and/or transvaginal ultrasound, fifty patients with large uterine fibroids ≥5cm3, and fifty patients with small uterine fibroid<5cm3. Serum lipid profile was measured in both groups in fasting state for comparison.
Results: The most common complaint was abnormal uterine bleeding in both groups. body mass index were 20-29.9; and significant difference between group1 that showed a lower levels of high-density lipoprotein 40.82±9.4, higher levels of low-density lipoprotein 94.79±35.07 and total serum cholesterol 155.7±43.63 and group 2 that showed higher level of high density lipoprotein 50.7±6.55, lower level of low density lipoprotein 51.49±15.2 and total cholesterol 123.2±14.18 with p value <0.001.while non-significant difference between the two groups in term of very low density lipoprotein with p value 0.878 and triglyceride with p value 0.879.
Conclusions: Dyslipidemia in the form of low high density lipoprotein, high low density lipoprotein and high cholesterol was significantly associated with increased size of uterine fibroid.
Metrics
References
Drayer SM, Catherino WH. Prevalence, morbidity, and current medical management of uterine leiomyomas. Int J Gynecol Obstet. 2015;131(2):117-22.
Parker WH, Pritts EA, Olive DL. What is the future of open intraperitoneal power-morcellation of fibroids?. Clin Obstet Gynecol. 2016;59(1):73-84.
Donnez J, Donnez O, Dolmans MM. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?. Fertil Steril. 2014;102(3):640-8.
Otify M, Critchley HO. pathophysiology of uterine fibroids. Modern Management of Uterine Fibroids. 2020:1.
Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of uterine fibroids. InSeminars Reproduct Med. 2010;28(03):204-17.
Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Women's Heal. 2014;6:95.
Styer AK, Rueda BR. The epidemiology and genetics of uterine leiomyoma. Best pract Res Clin Obstet Gynaecol. 2016;34:3-12.
Mehine M, Kaasinen E, Aaltonen LA. Chromothripsis in uterine leiomyomas. N Eng Med. 2013;369(22):2160-1.
Mehine M, Mäkinen N, Heinonen HR, Aaltonen LA, Vahteristo P. Genomics of uterine leiomyomas: insights from high-throughput sequencing. Fert Ste. 2014;102(3):621-9.
Van den Bosch T. Benign disease of the uterus.in: Edmonds DK, Lees C, Bourne T., eds. Dewhurst's Textbook of Obstetrics & Gynaecology. 9th ed. Blackwell; 2018:826-832.
Stewart EA, Nicholson WK, Bradley L, Borah BJ. The burden of uterine fibroids for African-American women: results of a national survey. J Women's Heal. 2013;22(10):807-16.
Brölmann H, Tanos V, Grimbizis G, Ind T, Philips K, van den Bosch T, et al. Options on fibroid morcellation: a literature review. Gynecol Surg. 2015;12(1):3-15.
Amant F, Van den Bosch T, Vergote I, Timmerman D. Morcellation of uterine leiomyomas: a plea for patient triage. Lancet Oncol. 2015;16(15):1454-6.
Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinol. 2010;151(6):2433-42.
McWilliams MM, Chennathukuzhi VM. Recent advances in uterine fibroid etiology. InSeminars Reproduct Med. 2017;35(2):181.
Reis FM, Bloise E, Ortiga-Carvalho TM. Hormones and pathogenesis of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:13-24.
Hoffman BL. Benign uterine pathology In: Schorge JO, Halvorson LM, Hamid CA, Corton MM, Schaffer JI, eds. Williams Gynecology. 4th ed. New York: McGraw-Hill; 2020:204-215.
Ahmed S, Shah P, Ahmed O. Biochemistry, Lipids. Treasure Island, FL: StatPearls Publishing; 2023.
Soave I, Marci R. From obesity to uterine fibroids: an intricate network. Current medical research and opinion. 2018;34(11):1877-9.
Zeybek B, Costantine M, Kilic GS, Borahay MA. Therapeutic roles of statins in gynecology and obstetrics: the current evidence. Reproduct Sci. 2018;25(6):802-17.
Borahay MA, Fang X, Baillargeon JG, Kilic GS, Boehning DF, Kuo YF. Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study. Ame J Obstet Gynecol. 2016;215(6):750-e1.
Kaur KK, Allahbadia GN, Singh M. Use of 20mg statins (atorvastatin/simvastatin) as a novel new option of medically treating fibroids-overcoming the drawback of selective progesterone receptor modulators of interruption before long term use. Int J Pregn Chi Birth. 2019;5(3):116-7.
Shavell VI, Thakur M, Sawant A, Kruger ML, Jones TB, Singh M, et al. Adverse obstetric outcomes associated with sonographically identified large uterine fibroids. Fertil Steri. 2012;97(1):107-10.
Ciavattini A, Clemente N, Delli Carpini G, Di Giuseppe J, Giannubilo SR, et al. Number and size of uterine fibroids and obstetric outcomes. J Maternal-Fet Neonat Med. 2015;28(4):484-8.
Sarkodie BD, Botwe BO, Adjei DN, Ofori E. Factors associated with uterine fibroid in Ghanaian women undergoing pelvic scans with suspected uterine fibroid. Fertility Res Pract. 2016;2(1):1-7.
Sharami SH, Arzpeyma SF, Shakiba M, Montazeri S, Milani F, Kazemi S, et al. Relationship of uterine fibroids with lipid profile, anthropometric characteristics, subcutaneous and preperitoneal fat thickness. Arch Iran Med. 2019;22(12):716-21.
Sersam LW. Study of lipid profile in patients with uterine fibroid. Iraqi Acad Scient J. 2012;11(2):274-9.
Kong S, Hou J, Xia M, Yang Y, Xu A, Tang Q. Association of hyperglycemia, hyperlipemia with the risk of uterine leiomyomata: a case-control study. Cancer Cell Res. 2014;2(1):37-41.
Afruza S, Hossain AA, Jahan J, Sharmin A, Naznin H, Shameem M. Association of dyslipidemia with uterine fibroid: a case control study. TAJ: J Teach Assoc. 2020;33(2):100-6.
Vignini A, Sabbatinelli J, Clemente N, Delli Carpini G, Tassetti M, Zagaglia G, et al. Preperitoneal fat thicknesses, lipid profile, and oxidative status in women with uterine fibroids. Reproductive Sci. 2017;24(10):1419-25.
Sadlonova J, Kostal M, Smahelova A, Hendl J, Starkova J, Nachtigal P. Selected metabolic parameters and the risk for uterine fibroids. Int J Gynecol Obstetrics. 2008;102(1):50-4.
Akinlua OC, Ojo OC. Biochemical changes in fibroid patients. Advances Life Sci Tech. 2013;13:6-8.
Parazzini F, Chiaffarino F, Polverino G, Chiantera V, Surace M, La Vecchia C. Uterine fibroids risk and history of selected medical conditions linked with female hormones. Euro J Epidemiol. 2004;19(3):249-53.
Swarnalatha PK, Ebrahim NK. A correlative study of estrogen and lipid profile in premenopausal and postmenopausal women. Int J Biome Adv Res. 2012;3(11):818-22.
Downloads
Published
How to Cite
Issue
Section
